Condition (MeSH)
Heart Septal Defects, Ventricular
ClinicalTrials.gov lists 57 trials for Heart Septal Defects, Ventricular or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
52 of the 57 trials are tagged with Heart Septal Defects, Ventricular itself; the rest are tagged with a narrower condition beneath it.
When did Heart Septal Defects, Ventricular trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 1 |
Showing 10 of 27 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Heart Septal Defects, Ventricular trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 16 |
| Observational | 27 |
How many Heart Septal Defects, Ventricular trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Completed | 35 |
| Terminated | 4 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Heart Septal Defects, Ventricular trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 4 |
| Abbott Medical Devices | 2 |
| Asklepion Pharmaceuticals, LLC | 2 |
| Kayseri City Hospital | 2 |
Which drugs are being tested for Heart Septal Defects, Ventricular? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| L-Citrulline | 2 |
| L Carnitine | 1 |
| DEXMEDETOMIDINE | 1 |
| PMI-150 (intranasal ketamine) | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Salbutamol MDI | 1 |
| Norflouran (Placebo Evohaler(R) ) | 1 |
| Propranolol PO | 1 |
| MRI | 1 |
| urine collection | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Heart Septal Defects, Ventricular trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Elective Cardiac Surgery | 13 | 1 |
| Blood Loss | 8 | 2 |
| PA Band Removal | 7 | 1 |
| Abnormal Lab Value | 6 | 1 |
| Elective Procedure | 6 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Heart Septal Defects, Ventricular? (121)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Intra-aortic balloon pump implantation in early-stage cardiogenic shock reduces 30-day mortality in patients with ventricular septal defect following myocardial infarction. | International journal of cardiology | 2026 | Yes |
| Health and Well-Being in Older Adults With a Surgically Closed or an Unrepaired Ventricular Septal Defect. | Journal of the American Heart Association | 2023 | Yes |
| Transcatheter Closure of Atrial and Ventricular Septal Defects: JACC Focus Seminar. | Journal of the American College of Cardiology | 2022 | Yes |
| Altered Cerebral Microstructure in Adults With Atrial Septal Defect and Ventricular Septal Defect Repaired in Childhood. | Journal of the American Heart Association | 2022 | Yes |
| Abnormal Left-Hemispheric Sulcal Patterns in Adults With Simple Congenital Heart Defects Repaired in Childhood. | Journal of the American Heart Association | 2021 | Yes |
Showing 5 of 121 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.